- Home
- APRE vs SBFM Comparison
APRE vs SBFM Comparison
Compare APRE & SBFM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | APRE | SBFM |
|---|---|---|
| Founded | 2006 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.9M | 7.2M |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | APRE | SBFM |
|---|---|---|
| Price | $0.95 | $1.43 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $20.00 | $7.00 |
| AVG Volume (30 Days) | ★ 71.8K | 66.6K |
| Earning Date | 11-12-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $488,239.00 | ★ $37,323,742.00 |
| Revenue This Year | N/A | $10.26 |
| Revenue Next Year | N/A | $32.63 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 13.24 |
| 52 Week Low | $0.90 | $1.17 |
| 52 Week High | $5.00 | $3.90 |
Technical Indicators
Market Signals| Indicator | APRE | SBFM |
|---|---|---|
| Relative Strength Index (RSI) | 30.90 | 34.27 |
| Support Level | $0.90 | $1.43 |
| Resistance Level | $1.14 | $1.49 |
| Average True Range (ATR) | 0.09 | 0.06 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 8.98 | 0.00 |
Price Performance
Historical ComparisonAbout APRE Aprea Therapeutics Inc.
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.
About SBFM Sunshine Biopharma Inc.
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. Through its subsidiaries, the company has various generic prescription drugs on the market in Canada and is also involved in developing and selling OTC supplements. In addition, the company is conducting a proprietary drug development program, which is comprised of K1.1 mRNA targeted for liver cancer and SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections.